| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $38,245,467 ) (Continued on the next page) |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01DK138665 | Targeting bile acid composition to treat metabolic diseases | 000 | 2 | NIH | 12/31/2024 | $599,308 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA241845 | Validation of epigenomic biomarkers for thyroid cancer diagnostics | 001 | 4 | NIH | 6/2/2025 | $81,912 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA241845 | Validation of epigenomic biomarkers for thyroid cancer diagnostics | 000 | 4 | NIH | 11/13/2024 | $737,207 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | UM1CA186717 | Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN | 002 | 9 | NIH | 5/28/2025 | $190,341 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | UM1CA186717 | Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN | 001 | 9 | NIH | 4/21/2025 | $1,713,060 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R37CA292678 | The role, mechanism, and therapeutic potential of METTL1 in acute myeloid leukemia | 000 | 2 | NIH | 5/12/2025 | $434,632 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | K01DK128387 | The role of Nrf2 in beta cell expansion during pregnancy | 003 | 4 | NIH | 5/28/2025 | $14,056 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | K01DK128387 | The role of Nrf2 in beta cell expansion during pregnancy | 001 | 4 | NIH | 12/6/2024 | $153,554 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA266665 | Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer | 001 | 4 | NIH | 6/3/2025 | $60,090 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA266665 | Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer | 000 | 4 | NIH | 12/19/2024 | $540,806 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01HL162847 | Pathogenesis, prevention and treatment of corticosteroid-resistant gut GVHD | 000 | 3 | NIH | 12/20/2024 | $771,055 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R25CA275711 | Cancer Aging and Metabolism research experience Program (CAMP) | 000 | 2 | NIH | 6/2/2025 | $238,924 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA258778 | Targeting tumor-associated macrophages for triple-negative breast cancer treatment | 001 | 4 | NIH | 5/29/2025 | $51,959 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA258778 | Targeting tumor-associated macrophages for triple-negative breast cancer treatment | 000 | 4 | NIH | 11/12/2024 | $467,633 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | P30CA033572 | Cancer Center Support Grant | 001 | 42 | NIH | 12/23/2024 | $199,548 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | P30CA033572 | Cancer Center Support Grant | 002 | 42 | NIH | 12/26/2024 | $249,999 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | P30CA033572 | Cancer Center Support Grant | 000 | 42 | NIH | 12/20/2024 | $3,536,183 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R03CA300614 | Evaluating the ELF5 Clock as a Biomarker in Breast Cancer Prevention Trials | 000 | 1 | NIH | 6/23/2025 | $178,000 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA269740 | Targeting the Microenvironment/Oncogene Cooperation to treat poor prognosis T-ALL | 001 | 3 | NIH | 5/23/2025 | $51,967 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA269740 | Targeting the Microenvironment/Oncogene Cooperation to treat poor prognosis T-ALL | 000 | 3 | NIH | 2/19/2025 | $467,705 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01DK137515 | Circadian clock and temporal control in nutrient metabolism | 000 | 3 | NIH | 6/18/2025 | $453,816 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01NS143100 | Novel Neurosurgical Device for Evacuation of Intracerebral Hematoma | 000 | 1 | NIH | 6/24/2025 | $439,239 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01ES034793 | Early Life Exposure to Endocrine Disrupting Chemicals: Epigenomic and Transcriptomic Networks and RAGE in Liver Disease | 000 | 2 | NIH | 3/27/2025 | $767,661 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA282450 | Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia | 000 | 3 | NIH | 6/30/2025 | $648,241 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA266783 | Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation | 001 | 3 | NIH | 5/23/2025 | $64,891 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA266783 | Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation | 000 | 3 | NIH | 3/31/2025 | $584,019 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01DK133885 | Extracellular Vesicle-mediated islet immune cross talk in Type 1 Diabetes pathogenesis | 000 | 4 | NIH | 5/30/2025 | $747,900 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01ES033514 | Environmental Chemical Body Burden and Prospective Breast Cancer Risk in the Cancer Prevention Study-3 Cohort | 000 | 4 | NIH | 4/10/2025 | $615,930 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA271497 | The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia | 001 | 4 | NIH | 5/29/2025 | $57,380 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA271497 | The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia | 000 | 4 | NIH | 1/24/2025 | $516,429 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA255250 | Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancer | 000 | 5 | NIH | 6/10/2025 | $431,501 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01HL173308 | Novel mechanisms and therapeutics for Tyrosine Kinase Inhibitor-induced Cardiotoxicity | 000 | 1 | NIH | 5/9/2025 | $697,952 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01NS132083 | Biological function and regulation of PRMT9 in synapse development | 000 | 2 | NIH | 3/4/2025 | $535,402 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01AG072291 | Develop age-relevant glial cellular models using human directly reprogrammed cells | 001 | 5 | NIH | 6/11/2025 | $35,200 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01AG072291 | Develop age-relevant glial cellular models using human directly reprogrammed cells | 000 | 5 | NIH | 5/12/2025 | $396,000 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA246553 | Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer | 001 | 6 | NIH | 5/28/2025 | $46,297 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA246553 | Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer | 000 | 6 | NIH | 3/28/2025 | $416,701 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA262754 | The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma | 000 | 5 | NIH | 7/1/2025 | $401,561 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA301510 | Discovery and validation of CYP8B1 Inhibitors as probes for targeting Hepatocellular Carcinomas (HCC) | 000 | 1 | NIH | 4/11/2025 | $793,324 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA299039 | The role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression | 000 | 1 | NIH | 4/3/2025 | $593,028 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01NS138604 | High Fidelity Genome Editing for the Correction of MECP2 Mutations and Physiologic Regulation of Expression in Rett Syndrome | 000 | 1 | NIH | 4/1/2025 | $738,182 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA228308 | The role of bile acid metabolomics in graft-versus-host disease | 001 | 8 | NIH | 5/6/2025 | $0 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA228308 | The role of bile acid metabolomics in graft-versus-host disease | 002 | 8 | NIH | 6/4/2025 | $58,584 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA228308 | The role of bile acid metabolomics in graft-versus-host disease | 000 | 8 | NIH | 3/31/2025 | $527,259 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R25CA217270 | Preparing Oncology Advanced Practice Nurses as Generalists in Palliative Care | 000 | 8 | NIH | 1/10/2025 | $291,600 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R25CA217270 | Preparing Oncology Advanced Practice Nurses as Generalists in Palliative Care | 001 | 8 | NIH | 2/12/2025 | $0 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA292596 | Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous Leukemia | 000 | 1 | NIH | 3/7/2025 | $738,698 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | T32CA186895 | DNA Damage Response and Oncogenic Signaling | 001 | 9 | NIH | 5/22/2025 | $4,056 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | T32CA186895 | DNA Damage Response and Oncogenic Signaling | 000 | 9 | NIH | 3/28/2025 | $245,477 |
|
